Search results
Results from the WOW.Com Content Network
The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. [1] India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports.
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
The company's first international move took it to Russia in 1992. There, Dr. Reddy's formed a joint venture with the country's biggest pharmaceuticals producer, Biomed.They pulled out in 1995 amid accusations of scandal, involving "a significant material loss due to the activities of Moscow's branch of Reddy's Labs with the help of Biomed's chief executive". [8]
Pages in category "Pharmaceutical companies of India" The following 63 pages are in this category, out of 63 total. This list may not reflect recent changes. A.
The distribution of medications has special drug safety and security considerations. [1] Some drugs require cold chain management in their distribution. [2]The industry uses track and trace technology, though the timings for implementation and the information required vary across different countries, with varying laws and standards.
City Major industrial sector Ahmedabad: Textiles, pharmaceuticals, chemicals, machinery, engineering Surat: Textiles, diamond cutting and polishing, chemicals, steel
India's largest multinational public sector life insurance company. 116 Indian Oil Corporation: $94,273 31,942 Indian Oil provides products and services all along the energy value chain, and is India's largest commercial entity. The firm has been on the Global 500 as long as the list has been recorded. 178 State Bank of India: $71,844 232,296
On 7 April 2014, India-based Sun Pharmaceutical and Japan-based Daiichi Sankyo jointly announced the sale of the entire 63.4% share of Ranbaxy from Daiichi Sankyo to Sun Pharmaceutical in a $4 billion all-share deal. Under these agreements, shareholders of Ranbaxy were to receive a 0.8 share of Sun Pharmaceutical for each share of Ranbaxy. [3]